Please sign in to follow a disease.
T-cell large granular lymphocyte leukemia
MONDO:0019469T-cell large granular lymphocyte leukemia (T-cell LGL leukemia) is a lymphoproliferative malignancy that arises from the mature T-cell (CD3+) lineage.
Also known as: LGLL, T gamma lymphoproliferative disorder, T-LGL, T-LGL leukaemia, T-LGL leukemia, T-cell LGL leukaemia, T-cell LGL leukemia, T-cell large gran. lymph. leuk.
1970 clinical trials for this condition and its sub-types, 18 tagged with T-cell large granular lymphocyte leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug cocktail aims to tame rare blood cancers
Disease control Recruiting nowThis early-phase trial tests two drugs, ruxolitinib and duvelisib, together in people whose T- or NK-cell lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose of duvelisib when combined with a fixed dose of ruxolitinib. About 70 part…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for hard-to-treat BRAF cancers: drug targets tumor drivers
Disease control Recruiting nowThis study tests a drug called FORE8394 (plixorafenib) in people aged 10 and older whose cancers have specific BRAF gene changes. The goal is to see if the drug can shrink tumors or slow their growth. About 254 participants with advanced solid tumors or brain tumors will take the…
Phase 2 • Sponsor: Fore Biotherapeutics • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New hope for rare leukemia: ruxolitinib trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug ruxolitinib can shrink tumors in 30 adults with T-cell large granular lymphocyte leukemia, a rare blood cancer. Ruxolitinib works by blocking enzymes that cancer cells need to grow. The study will measure how many patients respond to trea…
Phase 2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for rare blood cancers: targeted drug trial opens
Disease control Recruiting nowThis study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have not responded to standard therapy. The goal is to see if the drug can shrink or control the cancer. About 48 adults will take the drug by mouth, and researchers…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Old drug, new hope? thalidomide trial targets rare leukemia
Disease control Recruiting nowThis phase 2 trial tests thalidomide, a drug once used for other conditions, in 48 people with symptomatic large granular lymphocytic (LGL) leukemia. Participants start on thalidomide alone; if it doesn't work well enough, methotrexate is added. The goal is to see if thalidomide …
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Massive new registry to track thousands of blood cancer patients for years
Knowledge-focused Recruiting nowThis study is a registry that will follow up to 8,000 people with chronic lymphocytic leukemia (CLL) and related blood cancers over many years. It does not test a new treatment but instead collects information on how patients are doing over time, including survival. The goal is t…
Sponsor: German CLL Study Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC